NanoString Technologies, Inc. ( NSTG) Stock. Should you Buy or Sell? $ 15.96
0.21 (1.30 %)
NanoString Technologies, Inc. Analysis
Updated on 10-09-2022| Symbol | NSTG |
| Price | $15.96 |
| Beta | 1.910 |
| Volume Avg. | $771.87 thousand |
| Market Cap | $742.05 M |
| 52 Week Range | $11.12 - $59.6 |
NanoString Technologies, Inc. opened the day at $15.96 which is +'1.30 % on yesterday's close. NanoString Technologies, Inc. has a 52 week high of $59.6 and 52 week low of $11.12, which is a difference of $48.48. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $742.05 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy NanoString Technologies, Inc. for $742.05 M, it would take 15 years to get your money back. NanoString Technologies, Inc. are in the Medical Instruments & Supplies space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
NanoString Technologies, Inc. Stock Forecast - Is NanoString Technologies, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Strong Sell | |
| ROA Score | Neutral | |
| DE Score | Strong Buy | |
| PE Score | Strong Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Buy |
Growth and Value
| PE Ratio | -5.321 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -0.975 |
Valuing NanoString Technologies, Inc.
| Price Book Value Ratio | 6.577 | Price To Book Ratio | 6.577 |
| Price To Sales Ratio | 5.185 | Price Earnings Ratio | -5.321 |
How liquid is NanoString Technologies, Inc.
| Current Ratio | 6.842 |
| Quick Ratio | 5.859 |
Debt
| Debt Ratio | 0.727 | Debt Equity Ratio | 2.669 |
| Long Term Debt To Capitalization | 0.685 | Total Debt To Capitalization | 0.690 |
Latest news about NanoString Technologies, Inc.
SEATTLE--(BUSINESS WIRE)-- #earnings--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast presentations from two upcoming financial conferences. Morgan Stanley 20th Annual Global Healthcare Conference Monday, September 12th Brad Gray, NanoString's chief executive officer, will participate in a fireside discussion at 1:05pm ET. 2022 Baird Global Healthcare Conference Tu
NanoString Technologies, Inc. (NASDAQ:NSTG ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Doug Farrell - Vice President, Investor Relations Brad Gray - President and Chief Executive Officer Tom Bailey - Chief Financial Officer Conference Call Participants Alex Vukasin - Canaccord Genuity Dan Brennan - Cowen Edmund Debler - Morgan Stanley Dan Arias - Stifel Operator Hello and welcome to the NanoString Second Quarter Operating Results. My name is Katie, and I'll be coordinating your call today.
NanoString (NSTG) delivered earnings and revenue surprises of -37.10% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SEATTLE--(BUSINESS WIRE)-- #earnings--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast presentations from two upcoming healthcare conferences. 42nd Annual Canaccord Global Growth Conference Wednesday, August 10th Brad Gray, NanoString's chief executive officer, will participate in a spatial biology panel titled, “The New Frontier of Life Sciences: Spatial Omics is T
The consensus price target hints at a 171.7% upside potential for NanoString (NSTG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
About NanoString Technologies, Inc.
Description :
NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics. It has collaboration with Lam Research Corporation for the research and development of Hyb & Seq technologies; Celgene Corporation for developing LymphMark, an in vitro diagnostic for the treatment of diffuse large B-cell lymphoma; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington.
